Preclinical assessment of a novel small molecule inhibitor of tryptophan 2,3-dioxygenase 2 (TDO2) by Stefano Crosignani et al.
POSTER PRESENTATION Open Access
Preclinical assessment of a novel small molecule
inhibitor of tryptophan 2,3-dioxygenase 2 (TDO2)
Stefano Crosignani1, Gregory Driessens1, Michel Detheux1, Benoît Van den Eynde2, Sandra Cauwenberghs1*
From Society for Immunotherapy of Cancer 29th Annual Meeting
National Harbor, MD, USA. 6-9 November 2014
Introduction
iTeos leverages the science of LICR to target metabolism
of the tumor microenvironment and develops small mole-
cule immunomodulators. TDO2 is a heme-containing
enzyme highly expressed in the liver, in specific brain
regions and liver/brain tumors. It catalyses the first and
rate-limiting step of tryptophan catabolism along the
kynurenine pathway and thereby regulates systemic tryp-
tophan levels. Tryptophan (Trp) degradation by TDO2
suppresses anti-tumor immune responses and promotes
tumor cell survival.
Methods/results
Medicinal chemistry optimization following a primary
HTS (98,000 compound library) led to the selection of
three distinct chemical series. Compounds from all ser-
ies inhibit kynurenine production with comparable nM
potency compared to the earlier described Welcome
compound 680C91 in cellular assays (IC50 190-450nM
(A172)) and without activity on IDO1 (>100-fold selec-
tivity for TDO2). Compounds with low clearance and
half-lives of >1.5h in mice were identified for each of the
three series. A compound was selected for further in vivo
work due to its high oral bioavailability and long half-life
in mice (3.5h). TDO2 inhibition was followed by trypto-
phan quantification in the blood (vehicle 21.0 ± 1.1 versus
TDO2i (60mg/kg) 33.9 ± 1.51 μg/mL Trp; n = 10 mice/
group). In a time-course experiment, inhibition of trypto-
phan degradation lasted up to 16h with a dose of 60mg/kg
consistent with good rodent half-life. TDO2 inhibition in a
P815 Mastocytoma tumor model overexpressing TDO2
showed efficacy with the investigational TDO2i, LM10.
Further testing with an iTeos TDO2 compound with good
PK/PD profile is ongoing on liver tumor models (HCC,
liver metastases) as well as glioblastoma. A proprietary
antibody for hTDO2 was generated to screen 15 different
human cancer types (60 samples each) for TDO2 protein
expression. Differential quantification will allow selection
of putative clinical indications for TDO2 treatment in
stand-alone or combination with standard of care treat-
ment, vaccination or immune checkpoint inhibition.
Conclusions
iTeos’ drug discovery efforts have generated several scaf-
fold structures for first-in-class TDO2 small molecule
inhibitors suitable for in vitro and in vivo validation.
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